| scholarly article | Q13442814 |
| P50 | author | Paul Workman | Q7154482 |
| P2093 | author name string | Suzanne A Eccles | |
| Kevin J Harrington | |||
| Christopher M Nutting | |||
| Shreerang A Bhide | |||
| Shane Zaidi | |||
| Robert A Huddart | |||
| Martin McLaughlin | |||
| P2860 | cites work | NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models | Q21195221 |
| Chaperoning checkpoint kinase 1 (Chk1), an Hsp90 client, with purified chaperones | Q24298081 | ||
| Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma | Q24607424 | ||
| Chromosome breakage after G2 checkpoint release | Q24683383 | ||
| 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer | Q27649087 | ||
| Cell death by mitotic catastrophe: a molecular definition | Q28255830 | ||
| Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models | Q28275413 | ||
| NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis | Q28276567 | ||
| Targeting the dynamic HSP90 complex in cancer | Q28288602 | ||
| Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress | Q28303213 | ||
| A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. | Q51549127 | ||
| The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. | Q55044969 | ||
| A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study | Q79961136 | ||
| HSP72 depletion suppresses gammaH2AX activation by genotoxic stresses via p53/p21 signaling | Q82452820 | ||
| A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors | Q28304273 | ||
| Structure and mechanism of the Hsp90 molecular chaperone machinery | Q29615146 | ||
| Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study | Q33390600 | ||
| Guidelines for the welfare and use of animals in cancer research | Q33903753 | ||
| The Hsp90 molecular chaperone: an open and shut case for treatment | Q34753043 | ||
| A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer | Q34898930 | ||
| Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. | Q35127277 | ||
| Inhibition of Hsp90: a multitarget approach to radiosensitization | Q36899860 | ||
| HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair | Q37163368 | ||
| Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90 | Q37309929 | ||
| Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage | Q39544077 | ||
| Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction | Q39700328 | ||
| Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800. | Q39718180 | ||
| (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft | Q39758832 | ||
| The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe | Q39799336 | ||
| BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy | Q39815503 | ||
| Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. | Q39982294 | ||
| Triggering senescence programs suppresses Chk1 kinase and sensitizes cells to genotoxic stresses | Q40002547 | ||
| Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo. | Q40117631 | ||
| Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51. | Q40164528 | ||
| Hsp90 regulates the Fanconi anemia DNA damage response pathway | Q40165693 | ||
| Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin | Q40212276 | ||
| Induction of the 72-kilodalton heat shock protein and protection from ultraviolet B-induced cell death in human keratinocytes by repetitive exposure to heat shock or 15-deoxy-delta(12,14)-prostaglandin J2. | Q40298208 | ||
| Heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin potentiates the radiation response of tumor cells grown as monolayer cultures and spheroids by inducing apoptosis | Q40338078 | ||
| ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition | Q40390311 | ||
| Preferential sensitization of tumor cells to radiation by heat shock protein 90 inhibitor geldanamycin | Q40403419 | ||
| Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin | Q40483294 | ||
| Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. | Q40572671 | ||
| Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation | Q40600964 | ||
| Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress | Q40624388 | ||
| Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization | Q40632085 | ||
| Geldanamycin promotes premature mitotic entry and micronucleation in irradiated p53/p21 deficient colon carcinoma cells | Q42930980 | ||
| 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. | Q43097928 | ||
| Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. | Q44705946 | ||
| Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies | Q46551678 | ||
| Radiosensitization of human vascular endothelial cells through Hsp90 inhibition with 17-N-allilamino-17-demethoxygeldanamycin | Q46645739 | ||
| A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma | Q48474924 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | DNA damage | Q5205747 |
| luminespib | Q10859697 | ||
| P304 | page(s) | e35436 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage | |
| P478 | volume | 7 |
| Q64230423 | 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition |
| Q37536525 | A novel HSP90 inhibitor with reduced hepatotoxicity synergizes with radiotherapy to induce apoptosis, abrogate clonogenic survival, and improve tumor control in models of colorectal cancer |
| Q38921651 | A selenium-containing ruthenium complex as a cancer radiosensitizer, rational design and the important role of ROS-mediated signalling |
| Q42743031 | Both the charged linker region and ATPase domain of Hsp90 are essential for Rad51-dependent DNA repair |
| Q57176137 | Combined ATR and DNA-PK Inhibition Radiosensitizes Tumor Cells Independently of Their p53 Status |
| Q34770140 | Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma |
| Q33820264 | Critical role of aberrant angiogenesis in the development of tumor hypoxia and associated radioresistance |
| Q42363700 | Dual PI3K- and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: The role of drug-irradiation schedule |
| Q38555907 | From novel insights in molecular biology to targeted treatment approaches in head and neck cancer |
| Q37615630 | HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation |
| Q47738263 | Heat shock proteins and DNA repair mechanisms: an updated overview |
| Q90197699 | Heat-shock proteins: chaperoning DNA repair |
| Q37470072 | Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation |
| Q51754497 | Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma. |
| Q26778944 | Hsp90: A New Player in DNA Repair? |
| Q36307472 | Induction of Hsp70 in tumor cells treated with inhibitors of the Hsp90 activity: A predictive marker and promising target for radiosensitization |
| Q37031569 | Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment |
| Q37092020 | Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer. |
| Q39203018 | Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells. |
| Q90381124 | Radiosensitization of HSF-1 Knockdown Lung Cancer Cells by Low Concentrations of Hsp90 Inhibitor NVP-AUY922 |
| Q37403232 | Radiosensitizers in pancreatic cancer--preclinical and clinical exploits with molecularly targeted agents. |
| Q38648236 | Realistic biological approaches for improving thermoradiotherapy. |
| Q35200273 | Regulators of homologous recombination repair as novel targets for cancer treatment. |
| Q35818450 | The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells |
| Q35236805 | The combination of Hsp90 inhibitor 17AAG and heavy-ion irradiation provides effective tumor control in human lung cancer cells |
| Q36546425 | The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells |
| Q64977994 | Translational research in radiation-induced DNA damage signaling and repair. |
Search more.